NOVO.B.DK

259.2

-1.41%↓

GMAB.DK

1,658

-0.93%↓

HLUNB.DK

42.02

-0.43%↓

ZEAL.DK

301.9

-1.21%↓

AMBUB.DK

62.2

+0.08%↑

NOVO.B.DK

259.2

-1.41%↓

GMAB.DK

1,658

-0.93%↓

HLUNB.DK

42.02

-0.43%↓

ZEAL.DK

301.9

-1.21%↓

AMBUB.DK

62.2

+0.08%↑

NOVO.B.DK

259.2

-1.41%↓

GMAB.DK

1,658

-0.93%↓

HLUNB.DK

42.02

-0.43%↓

ZEAL.DK

301.9

-1.21%↓

AMBUB.DK

62.2

+0.08%↑

NOVO.B.DK

259.2

-1.41%↓

GMAB.DK

1,658

-0.93%↓

HLUNB.DK

42.02

-0.43%↓

ZEAL.DK

301.9

-1.21%↓

AMBUB.DK

62.2

+0.08%↑

NOVO.B.DK

259.2

-1.41%↓

GMAB.DK

1,658

-0.93%↓

HLUNB.DK

42.02

-0.43%↓

ZEAL.DK

301.9

-1.21%↓

AMBUB.DK

62.2

+0.08%↑

Search

Coloplast A-S (Class B)

Ouvert

393.1 -2.48

Résumé

Variation du prix de l'action

24h

Actuel

Min

390.6

Max

404.6

Chiffres clés

By Trading Economics

Revenu

522M

1.4B

Ventes

83M

7B

P/E

Moyenne du Secteur

22.883

67.147

BPA

6.32

Rendement du dividende

5.69

Marge bénéficiaire

19.835

Employés

16,983

EBITDA

309M

2.3B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

5.69%

2.36%

Prochains Résultats

12 mai 2026

Date du Prochain Dividende

20 mai 2026

Date du Prochain Détachement de Dividende

18 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-27B

91B

Ouverture précédente

395.58

Clôture précédente

393.1

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 avr. 2026, 23:53 UTC

Résultats

Naver Posts Weaker First-Quarter Earnings

29 avr. 2026, 23:41 UTC

Actions en Tendance

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 avr. 2026, 23:55 UTC

Résultats

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 avr. 2026, 23:54 UTC

Résultats

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 avr. 2026, 23:52 UTC

Résultats

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 avr. 2026, 23:51 UTC

Résultats

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 avr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 avr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 avr. 2026, 23:22 UTC

Résultats

China Longyuan 1Q Net CNY1.70B, Down 14%

29 avr. 2026, 23:22 UTC

Résultats

China Longyuan: Power Generation Down 2.9% as of End-March

29 avr. 2026, 23:20 UTC

Résultats

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 avr. 2026, 23:20 UTC

Résultats

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Loss Narrows>000002.SZ

29 avr. 2026, 23:18 UTC

Résultats

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 avr. 2026, 23:17 UTC

Résultats

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 avr. 2026, 23:15 UTC

Résultats

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 avr. 2026, 23:15 UTC

Résultats

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 avr. 2026, 23:13 UTC

Résultats

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 avr. 2026, 23:12 UTC

Résultats

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 avr. 2026, 23:11 UTC

Résultats

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 avr. 2026, 23:11 UTC

Résultats

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 avr. 2026, 23:04 UTC

Résultats

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 avr. 2026, 23:04 UTC

Résultats

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparaison

Variation de prix

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat